Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target



Prothena will...

Related Keywords

Richard Hargreaves ,Prothena Corporation ,Bristol Myers Squibb ,Exchange Commission ,Company On Twitter Prothenacorp ,Nasdaq ,Drug Administration ,Gene Kinney ,Chief Executive Officer ,Senior Vice President ,Neuroscience Thematic Research ,Quarterly Report ,